STOCK TITAN

Opus Genetics (IRD) Debt by Year

IRD NASDAQ

Opus Genetics, Inc. carried $1.1M in long-term debt against $45.1M in cash and equivalents at the end of fiscal year 2025. The change in long-term debt from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Opus Genetics, Inc. has filed alongside them.

FY2025 annual
Long-Term Debt $1.1M
Cash & Equivalents $45.1M
YoY n/m

Ticker history: OCUP became IRD (Opus Genetics, Inc.) on . Earlier news and filings retain their original names and dates. View OCUP history.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

IRD Debt & Cash by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-QFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-QFY14FilingFY13FilingFY1210-KFY1110-K
Long-Term Debt$1.1Mn/m$0N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Cash & Equivalents$45.1M+48.7%$30.3M-40.0%$50.5M+18.5%$42.6M+73.8%$24.5M+49.6%$16.4M+966.9%$1.5M-82.4%$8.7M-1.7%$8.9M-23.1%$11.6M+13.5%$10.2M+3.8%$9.8M-47.4%$18.7M+38.6%$13.5M+36.8%$9.9M

IRD Debt & Cash by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
Long-Term Debt$35.7M+3238.1%$35.3M+3428.1%$1.2M$1.1Mn/m$1.1M$1.0MN/A$0N/AN/AN/AN/A
Cash & Equivalents$89.0M+188.7%$88.8M+173.9%$60.0M+43.5%$45.1M+48.7%$30.8M-15.9%$32.4M-21.7%$41.8M-11.4%$30.3M-40.0%$36.6M-13.5%$41.4M+3.6%$47.2M+21.0%$50.5M+18.5%

What long-term debt means

Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.

More Opus Genetics, Inc. financials

Frequently Asked Questions

Opus Genetics, Inc. carried $1.1M in long-term debt against $45.1M in cash and equivalents at the end of fiscal year 2025.

Opus Genetics, Inc. (IRD) reported $0 in long-term debt in fiscal year 2024 and $1.1M in long-term debt in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.

Opus Genetics, Inc. (IRD) reported $35.7M in long-term debt in Q3 2026. This represents an increase of 3238.1% from the same quarter a year earlier.

Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Opus Genetics, Inc. (IRD) reported on that line in every period on record.